

Freedom of Information Request

Ref: UHB 20-037

31 January 2020

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?
01-Jul-2019 - 31-Dec-2019: 107 patients.
2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
Locally advanced
Recurrent metastatic
Unknown
The Trust does not hold this information.
3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?
Carboplatin (only or in combination with 5-FU): 3
Cisplatin (only or in combination with 5-FU): 33
Cetuximab with/without chemotherapy: 2
Cetuximab with radiotherapy: 1
Pembrolizumab monotherapy: 0

Pembrolizumab with chemotherapy: 0

Nivolumab: 5

Docetaxel (only or in combination with 5-FU): 0

Fluorouracil (5FU): 0

Radiotherapy only: 53

Other: 2

Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

Project Title	Tumour site	Portfolio Banding	Project phase	Principal Investigator	Project type	Date open to recruitment	Total recruited over study lifetime	Q1	Q2	Q3	Q4	Project site actual recruitment end date, if applicable
Best-of ("Best of" Radiotherapy vs "Best of" Surgery)	Head & Neck	Band 3	Phase III	Beasley, Dr Matthew	Non-commercial portfolio	22/02/2019	0	0	0	0	0	
Cabozantinib in Radioiodine-Refractory Differentiated Thyroid Cancer (Cosmic-311)	Head & Neck	Commercial - Portfolio	Phase III	Owadally, Dr Waheeda	Commercial portfolio	30/08/2019	0	0	0	0	0	
CompARE Trial, Version 1.0	Head & Neck	Band 3	Phase III	Booz, Dr Hoda	Non-commercial portfolio	22/09/2016	17	2	1	1	0	
IoN	Head & Neck	Band 3	Phase II/III	Beasley, Dr Matthew	Non-commercial portfolio	24/05/2012	49	3	1	0	0	
NATT (interNational Anaplastic Thyroid Cancer Tissue Bank and Database Project)	Head & Neck	Non-Portfolio	Not Applicable	Beasley, Dr Matthew	Non-commercial non-portfolio	24/05/2017	6	0	0	1	2	

NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer)	Head & Neck	Band 3	Phase III	Booz, Dr Hoda	Non- commercial portfolio	12/08/2014	22	2	0	0	0	23/05/2019
Pathos Postoperative adjuvant treatment for HPVpositive tumours	Head & Neck	Band 3	Phase II/III	Beasley, Dr Matthew	Non- commercial portfolio	11/02/2016	11	1	0	1	1	
SEL-I-METRY	Head & Neck	Band 3	Not Applicable	Beasley, Dr Matthew	Non- commercial portfolio	03/10/2017	11	3	2	0	0	15/08/2019

Please note: Head and Neck studies: 5 Head and Neck studies open (2 have closed to recruitment in this financial year- Nimrad and Sel-i-metry).

1. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];

Aflibercept: 0

Bevacizumab: 0

Capecitabine: 46

CAPIRI: 0

CAPOX: 0 (see XELOX below)

Cetuximab not in combination with FOLFIRI or FOLFOX: 0

Cetuximab in combination with FOLFIRI: 0

Cetuximab in combination with FOLFOX: 0

Irinotecan: 0

FOLFIRI: 23

FOLFOX: 4

Oxaliplatin: 0

Panitumumab not in combination with FOLFIRI or FOLFOX: 1

Panitumumab in combination with FOLFIRI: 6
Panitumumab in combination with FOLFOX: 0
Nivolumab: 2
Raltitrexed: 1
Ramucirumab: 0
Regorafenib: 0
Sorafenib: 0
5FU only: 0
Tegafur Uracil + 5FU: 0
Trifluridine–tipiracil: 10
XELOX: 73
Other: 23

2. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell

Carcinoma :

Sunitinib: 20

Avelumab + Axitinib: 3

Axitinib: 7

Cabozantinib: 13

Everolimus: 0

Lenvantinib + Everolimus: 0

Nivolumab: 10

Nivolumab + Ipilimumab: 2

Pazopanib: 8

Pembrolizumab + Axitinib: 0

Sunitinib: Please see above

Temsirolimus: 0

Tivozanib: 5

3. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

Project Title	Tumour site	Portfolio Banding	Project phase	Principal Investigator	Project type	Date open to recruitment	Total recruited over study lifetime	Q1	Q2	Q3	Q4	Project site actual recruitment end date, if applicable
PRISM Trial	Urology	Band 3	Phase II	Bahl, Dr Amit	Non-commercial portfolio	05/07/2019	1	0	0	1	0	06/12/2019
Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)	Urology	Band 3	Phase III	Bahl, Dr Amit	Non-commercial portfolio	24/07/2019	1	0	0	1	0	

1 open – Rampart (1 also closed to recruitment in this financial year – Prism).

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance
University Hospitals Bristol NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

FOI Team
UH Bristol NHS Foundation Trust